Skip to main content

Selling your emerging life-science company: Earnouts and special holdbacks hitting your closing-date payout

New York Member James McKnight authored this column discussing what PE firms can do to secure their finances when facing earnouts and special holdbacks in selling emerging life-science companies.


The PE Hub Network